Cardiovascular medicine is being reshaped by clinical AI, precision imaging, better prevention and connected care. The people worth following are the cardiologists who help explain what those changes mean for patients and clinical practice.
These 25 cardiologists bring distinct perspectives on the field, from the design of major trials to the practical demands of a remote device clinic. For clinicians, founders, investors and healthcare leaders, this is a guide to building a more informed professional network, organised around the work each person contributes.
The selection spans imaging, interventional cardiology, prevention, women’s heart health, heart failure and electrophysiology. Start with the areas closest to your work, then explore the evidence and ideas behind each profile.
How this list was selected
This is an editorial shortlist for professional discovery, rather than a ranking of clinical skill. Selection considered documented contributions to cardiovascular medicine, relevance to healthcare innovation or delivery, and professional profiles that help readers explore that work. Where no LinkedIn account was confirmed, an institutional biography is provided instead.
Institutional biographies, professional societies, original research, and official appointment announcements underpin the profiles. The reasons to follow are our editorial assessment of that work. Numbering identifies entries; it does not imply a clinical hierarchy. Posting frequency varies, and inclusion does not promise a regularly active LinkedIn feed.
Institutional sources were reviewed for this edition on 9 October 2026. LinkedIn can require sign-in; 24 LinkedIn destinations are linked below. For Barbara Casadei, whose LinkedIn account could not be confirmed, an institutional profile is provided instead of an invented destination. Commercial affiliations are named where relevant. The list is selective, with substantial US and European representation, rather than a comprehensive picture of cardiology worldwide.
1. Eric Topol
Clinical AI, precision medicine and patient agency
Eric Topol is a practising cardiologist at Scripps Clinic whose work connects cardiovascular care with genomics, digital technology and personalised medicine. His clinical background gives his writing on emerging technology a useful point of reference: the decisions patients and physicians actually face.
His 2019 Nature Medicine review examined the convergence of human and artificial intelligence across healthcare. Alongside his clinical interests in preventive cardiology and coronary disease, that work makes him relevant to readers trying to understand how computational tools could change medical practice.
Why follow: Topol is a useful starting point for thinking about AI in the context of the wider patient experience. For healthtech teams, the editorial value lies in connecting technical progress with questions about clinician judgement, patient participation and the evidence needed before a promising tool becomes routine care.
Sources: Institutional biography | Scripps clinical biography | Nature Medicine review, 2019
2. Harlan Krumholz
Outcomes, research transparency and health system performance
Harlan Krumholz is a Yale cardiologist and the Harold H. Hines, Jr. Professor of Medicine. His research centres on the quality, equity and outcomes of healthcare, making him relevant to anyone who wants to look beyond a product’s technical capabilities.
He founded Yale’s Center for Outcomes Research and Evaluation and co-founded the Yale Open Data Access project, which supports access to clinical research data. He also co-founded medRxiv and is Editor In Chief of the Journal of the American College of Cardiology. These are distinct contributions to outcomes research, data access and scientific communication.
Why follow: Krumholz offers a strong reference point for asking whether an intervention makes care measurably better. His work is particularly useful when judging hospital performance, patient-centred outcomes and the transparency of the evidence behind a healthcare claim.
Follow Harlan Krumholz on LinkedIn
Sources: Institutional biography | Yale biography and research
3. Rohan Khera
Cardiovascular data science and AI-enabled diagnostics
Rohan Khera is a cardiologist and data scientist at Yale, where he leads the Cardiovascular Data Science, or CarDS, Lab. His work brings together electronic health records, electrocardiography and machine learning to investigate cardiovascular diagnosis and treatment.
He was senior author of a 2023 study examining detection of left ventricular systolic dysfunction from single-lead ECGs adapted for portable and wearable devices. The work addresses an important translation problem: signals collected outside a conventional clinical setting can differ from the data on which an algorithm was developed.
Why follow: Khera is especially relevant to readers building or evaluating clinical AI. His research gives them concrete questions to take into product discussions: what data trained the model, how was it validated, and how closely does the evaluation resemble the setting in which the tool will be used?
Follow Rohan Khera on LinkedIn
Sources: Institutional biography | Yale biography and publications | Single-lead ECG study, 2023
4. Ami Bhatt
Digital cardiology, consumer health and clinical integration
Ami Bhatt is a board-certified cardiologist who became chief medical officer of WHOOP in July 2026. Her earlier roles included chief innovation officer at the American College of Cardiology and inaugural chair of the US Food and Drug Administration’s Digital Health Advisory Committee.
WHOOP’s appointment announcement also describes her development of outpatient and telecardiology services at Massachusetts General Hospital. That combination of clinical delivery, professional society innovation, and consumer technology makes her career relevant to the boundary between everyday health data and medical care.
Why follow: Bhatt is a useful name for readers interested in how digital tools fit into healthcare relationships and workflows. Her move to WHOOP also makes the commercial context explicit: product development and clinical evaluation need to be considered together, rather than treating a clinician’s involvement as proof that every product claim has been established.
Sources: Institutional biography | WHOOP appointment announcement, July 2026
5. James K. Min
Coronary CT, plaque assessment and imaging entrepreneurship
James K. Min is a board-certified cardiologist and the founder and CEO of Cleerly, a company developing AI-based analysis of coronary CT angiography. Before founding the company, he was a professor at Weill Cornell Medicine and directed its Dalio Institute of Cardiovascular Imaging.
His research background includes leadership in studies such as CONFIRM and ICONIC, which investigated coronary imaging and atherosclerotic disease. The ICONIC study examined coronary features preceding acute coronary syndromes, offering an example of the evidence behind interest in plaque characterisation.
Why follow: Min is relevant to readers following the movement from cardiovascular imaging research into commercial software. His work helps frame the questions that matter beyond image analysis: whether an assessment changes a clinical decision, which patients benefit, and what additional evidence is needed to demonstrate improved outcomes. His company leadership is part of that context.
Follow James K. Min on LinkedIn
Sources: Institutional biography | Cleerly leadership biography | ICONIC study, 2018
6. Seth Shay Martin
Lipid measurement and digital prevention
Seth Shay Martin is a Johns Hopkins cardiologist whose work spans lipid disorders, prevention and digital health. His institutional biography identifies him as director of the Advanced Lipid Disorders Program and Digital Health Lab at the Ciccarone Center. He led development of an improved method for estimating LDL cholesterol, evaluated against the Friedewald equation in a 2013 JAMA paper. He is also a co-founder of the Corrie Health Digital Platform, which combines digital tools with support for guideline-directed cardiovascular care.
Why follow: Martin illustrates two different forms of healthcare innovation: improving a measurement used in everyday practice and redesigning the support patients receive around treatment. For readers evaluating digital prevention, his work is a reminder to ask both whether the underlying clinical information is reliable and whether a tool helps people act on it.
Follow Seth Shay Martin on LinkedIn
Sources: Institutional biography | Johns Hopkins biography | LDL estimation study, 2013
7. Francoise A. Marvel
Digital recovery after a heart attack
Francoise A. Marvel is a Johns Hopkins cardiologist whose work includes the Corrie digital health platform and cardiovascular care beyond the hospital. Her research makes the transition from acute treatment to everyday self-management a central part of the innovation discussion. Marvel and Erin Spaulding were joint first authors of a 2021 study of a digital intervention combining a smartphone app, smartwatch and blood pressure monitor after myocardial infarction. The intervention supported medication reminders, education, tracking and care coordination. The study used a historical control group; it was not a randomised trial.
Why follow: Marvel is particularly relevant to teams designing recovery and remote care services. Her work offers a concrete way to think about the patient’s first weeks at home, while the study design provides a useful reminder to distinguish an encouraging association from a definitive causal claim about a product.
Follow Francoise A. Marvel on LinkedIn
Sources: Institutional biography | Johns Hopkins expert announcement, 2026 | Digital intervention study, 2021
8. C. Michael Gibson
Coronary trial endpoints and cardiovascular research
C. Michael Gibson is an interventional cardiologist and cardiovascular clinical trial researcher. The Society for Cardiovascular Angiography and Interventions identifies him as CEO of the combined nonprofit Baim and PERFUSE research organisations. His documented contributions include the TIMI frame count, which quantifies coronary blood flow, and the TIMI myocardial perfusion grade, which assesses perfusion at the tissue level. These measures show why the methods used to evaluate a treatment can be as important as the treatment itself.
Why follow: Gibson is relevant to readers who want to understand how cardiovascular trials turn a clinical question into measurable evidence. For device and drug developers, that means looking carefully at endpoint selection, interpretation, and the relationship between an observed physiological change and an outcome that matters to patients.
Follow C. Michael Gibson on LinkedIn
Sources: Institutional biography | SCAI professional biography | TIMI frame count paper, 1996
9. Deepak L. Bhatt
Large cardiovascular trials and therapeutic evidence
Deepak L. Bhatt is an interventional cardiologist and director of the Mount Sinai Fuster Heart Hospital. His research career includes major studies of cardiovascular therapies, antithrombotic treatment, and coronary intervention. He was the lead author of the main REDUCE-IT publication, which evaluated prescription icosapent ethyl in statin-treated patients with elevated triglycerides and established cardiovascular disease or diabetes with additional risk factors. Naming the treatment and the population matters: evidence from this trial should not be casually relabeled as evidence for all fish-oil supplements.
Why follow: Bhatt is a useful reference for readers tracking how large trials shape treatment discussions. His work encourages a disciplined reading of a therapeutic claim: who was studied, what was compared, which endpoints were measured, and how closely the findings apply to the patients a service or product intends to reach.
Follow Deepak L. Bhatt on LinkedIn
Sources: Institutional biography | Mount Sinai appointment and research background | REDUCE-IT publication
10. Roxana Mehran
Interventional cardiology, bleeding risk and women’s representation
Roxana Mehran is a Mount Sinai interventional cardiologist and director of Interventional Cardiovascular Research and Clinical Trials. Her work includes clinical trials and risk assessment around coronary procedures, with particular attention to bleeding and other complications. She served as global principal investigator of TWILIGHT, a trial examining ticagrelor with or without continued aspirin after an initial period of dual antiplatelet therapy in selected high-risk patients undergoing coronary intervention. She also co-founded Women as One, which supports women physicians in cardiology.
Why follow: Mehran connects two important questions for cardiovascular innovation: how treatment benefits and harms are balanced, and who gets to contribute to the research and leadership behind those decisions. Her work is useful for readers considering trial design, procedural safety, and the representation of women within the profession.
Follow Roxana Mehran on LinkedIn
Sources: Institutional biography | Mount Sinai biography | Mount Sinai TWILIGHT research account | TWILIGHT publication, 2019
11. Robert A. Harrington
Clinical trial design and academic medicine
Robert A. Harrington is a cardiologist, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Cornell University’s provost for medical affairs. His clinical research background includes antithrombotic therapy in acute ischaemic heart disease and complications of coronary intervention. Before joining Weill Cornell, he chaired Stanford’s Department of Medicine and directed the Duke Clinical Research Institute. His official biography also highlights an interest in using technology to improve clinical trial methods. That makes his work relevant to the infrastructure through which cardiovascular evidence is generated.
Why follow: Harrington is a useful name for readers interested in the relationship between research, institutional leadership and care delivery. For founders and healthcare leaders, his perspective is relevant to a practical challenge: how to build credible studies within real clinical organisations, with the people and processes needed to carry them through.
Follow Robert A. Harrington on LinkedIn
Sources: Institutional biography | Weill Cornell leadership biography
12. Rasha Al-Lamee
Placebo-controlled trials and the treatment of stable angina
Rasha Al-Lamee is a clinical professor at Imperial College London and an interventional cardiologist. She designed and led ORBITA and is chief investigator of ORBITA-2, studies that brought placebo-controlled methods to an important question about coronary intervention. ORBITA-2 found a lower angina symptom score with PCI than with a placebo procedure at 12 weeks in patients with stable angina, objective evidence of ischaemia and little or no antianginal medication. The population, treatment context and symptom endpoint are essential to understanding the result.
Why follow: Al-Lamee is particularly relevant to readers who want to examine established practice with the same scrutiny applied to new technology. Her work offers a clear example of why a procedure’s effect on symptoms must be investigated carefully, and why a trial should not be reduced to a slogan about whether stents “work”.
Follow Rasha Al-Lamee on LinkedIn
Sources: Institutional biography | Imperial biography | ORBITA-2 publication, 2023
13. Mamas Mamas
Registries, real-world evidence and cardiovascular outcomes
Mamas Mamas is a professor of cardiology at Keele University and an honorary interventional cardiologist at Royal Stoke University Hospital. His research uses large clinical datasets to examine cardiovascular treatment and outcomes in routine practice. Keele describes his work with national and international data sources, including NICOR, the Clinical Practice Research Datalink, and US hospital datasets. His research interests include acute coronary syndromes, heart failure, coronary intervention and the effects of comorbidity. This is a different evidence lens from a tightly controlled clinical trial.
Why follow: Mamas is relevant to readers asking what happens when care reaches a broader, more complex population. His work helps frame questions about variation, complications and equity in everyday services. For healthtech teams, it also reinforces the need to understand data quality and confounding before interpreting a real-world association as a treatment effect.
Follow Mamas Mamas on LinkedIn
Sources: Institutional biography | Keele staff and research biography
14. Roger S. Blumenthal
Prevention, risk assessment and clinical guidelines
Roger S. Blumenthal is a Johns Hopkins preventive cardiologist and director of the Ciccarone Center for the Prevention of Cardiovascular Disease. His clinical and research interests include atherosclerosis, cardiovascular risk assessment and the use of imaging in prevention. He co-chaired the 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. That contribution is useful for understanding how multiple strands of evidence become recommendations intended for everyday clinical decisions, rather than remaining separate research findings.
Why follow: Blumenthal is a relevant name for readers developing prevention services, risk assessment tools or patient engagement programmes. His work puts a practical question at the centre of those efforts: once a person’s risk has been assessed, how should that information inform a conversation and a care plan? A score is only one part of the process.
Follow Roger S. Blumenthal on LinkedIn
Sources: Institutional biography | Johns Hopkins biography and guideline contribution
15. Khurram Nasir
Population health, prevention and the conditions of access
Khurram Nasir is a Houston Methodist cardiologist whose work combines cardiovascular prevention with population health and data science. Houston Methodist identifies him as chief of Cardiovascular Disease Prevention and Wellness. He co-authored a review on big data and digital solutions for cardiovascular population management. His research interests also include coronary artery calcium and risk assessment. Together, these areas connect the identification of risk with the much larger task of organising care across a population.
Why follow: Nasir is useful for readers who want prevention to reach beyond people who already navigate healthcare well. His work provides a starting point for thinking about segmentation, service design and the conditions that influence access. For healthcare leaders, the relevant question is how better information can support better delivery across communities, rather than stopping at an individual prediction.
Follow Khurram Nasir on LinkedIn
Sources: Institutional biography | Houston Methodist institutional profile | Population management review, 2020
16. Martha Gulati
Women’s cardiovascular care and the evaluation of chest pain
Martha Gulati is a cardiologist recruited by Houston Methodist in 2026 to lead its new Davis Women’s Cardiovascular Health Center. Her move is important context for readers familiar with her earlier work at Cedars-Sinai. She led the writing committee for the 2021 multisociety guideline on the evaluation and diagnosis of chest pain. Houston Methodist’s announcement describes a women’s cardiovascular programme bringing together clinical care, prevention and research. These contributions connect the assessment of symptoms with the organisation of care around women’s needs.
Why follow: Gulati is especially relevant to readers examining whether a diagnostic pathway or healthcare service reflects the patients it is meant to serve. Her work gives women’s cardiovascular health a substantive clinical focus, extending the discussion from awareness campaigns to assessment, evidence and the delivery of specialist care.
Follow Martha Gulati on LinkedIn
Sources: Institutional biography | Houston Methodist appointment, January 2026 | Chest pain guideline, 2021
17. Erin D. Michos
Women’s heart health, lipids and cardiometabolic prevention
Erin D. Michos is a professor of medicine at Johns Hopkins, director of Women’s Cardiovascular Health Research and associate director of Preventive Cardiology. Her work spans lipid management, cardiometabolic disease and the assessment of cardiovascular risk in women. Her institutional biography also identifies her as co-director of the IMPACT Center, which works to improve participation among diverse populations in cardiovascular clinical trials. Her clinical work includes preventive assessment for women with lipid disorders, family histories of heart disease and concerns around menopause.
Why follow: Michos is relevant to readers who want to connect prevention with the different stages and circumstances of women’s lives. Her work also brings trial participation into the discussion: the populations included in research matter when clinicians and product teams try to apply its findings to the people they serve.
Follow Erin D. Michos on LinkedIn
Sources: Institutional biography | Johns Hopkins biography | Johns Hopkins women’s cardiovascular team
18. Jennifer H. Mieres
Women’s heart health and public communication
Jennifer H. Mieres is a cardiologist associated with Northwell Health and the Zucker School of Medicine, with a longstanding focus on women’s cardiovascular health. Her work combines clinical medicine with public education and efforts to address disparities in care. The American Heart Association’s profile of Mieres describes her participation in Go Red for Women and her co-authorship of books including Heart Smart for Black Women and Latinas and Heart Smarter for Women. These projects illustrate an effort to make cardiovascular knowledge useful outside specialist settings.
Why follow: Mieres is a relevant name for anyone designing patient education, community engagement or communication around prevention. Her work prompts a practical test for healthcare messaging: can the intended audience recognise themselves in it, understand what it means and use it in a conversation about their health?
Follow Jennifer H. Mieres on LinkedIn
Sources: Institutional biography | American Heart Association profile | Zucker School institutional profile, 2023
19. Jane E. Wilcox
Heart failure, myocardial recovery and cardiomyopathy
Jane E. Wilcox is a Northwestern cardiologist specialising in advanced heart failure and transplantation. The Heart Failure Society of America identifies her as associate chief of cardiology and director of the Myocardial Recovery Clinic. Her research includes myocardial recovery, imaging and genetic cardiomyopathy. She was lead author of the 2020 JACC Scientific Expert Panel on heart failure with recovered left ventricular ejection fraction, examining a patient group whose improved measurements raise important questions about ongoing management.
Why follow: Wilcox is relevant to readers building longitudinal heart failure services or looking beyond a single clinical milestone. Her work helps keep recovery within a longer view of care: how improvement is characterised, how patients are followed and which questions remain after a measurement changes. That perspective is valuable when designing monitoring or support around chronic disease.
Follow Jane E. Wilcox on LinkedIn
Sources: Institutional biography | HFSA biography | JACC expert panel, 2020
20. Suneet Mittal
Electrophysiology and the remote device clinic
Suneet Mittal is a cardiac electrophysiologist at Valley Health System and medical director of its electrophysiology programme. His work is relevant to the growing operational demands of caring for people with implanted cardiac devices. He co-authored the 2023 HRS/EHRA/APHRS/LAHRS expert consensus statement on practical management of the remote device clinic. The document addresses the organisation of remote follow-up, moving the discussion beyond the ability of a device to transmit information.
Why follow: Mittal is a useful name for clinicians and healthtech teams thinking about remote monitoring as a service. Data transmission creates further questions about staffing, responsibility, communication and response. His clinical field and consensus contribution provide a practical basis for examining those questions when designing a connected care programme.
Follow Suneet Mittal on LinkedIn
Sources: Institutional biography | Valley electrophysiology team | Remote device clinic consensus, 2023
21. David Duncker
Wearables, arrhythmia detection and rhythm care
David Duncker is a cardiologist and electrophysiologist who leads the Hannover Heart Rhythm Center at Hannover Medical School. His clinical work and publications connect specialist rhythm care with digital devices and remote assessment. He co-authored the European Heart Rhythm Association’s practical guide on using digital devices to detect and manage arrhythmias. The guide is a useful reference for understanding the range of technologies involved, including ECG-based devices and tools that infer rhythm information from pulse signals.
Why follow: Duncker is particularly relevant to readers working with wearable cardiac data. His area of work helps frame the distinction between a signal, an alert and a clinically established diagnosis, as well as the pathway needed for appropriate review. Those distinctions matter when a consumer device becomes part of a healthcare interaction.
Follow David Duncker on LinkedIn
Sources: Institutional biography | Hannover Medical School clinical account | EHRA digital devices guide, 2022
22. John Mandrola
Electrophysiology, trial interpretation and clinical scepticism
John Mandrola is a cardiac electrophysiologist at Baptist Health in Louisville and a medical commentator. His public work includes writing for Medscape and the This Week in Cardiology podcast. His contribution to professional discussion is grounded in interpreting studies and examining the claims made about treatment and technology. That gives him a different place in this list from a product founder or trial principal investigator: the value is in the critical reading of evidence and the questions that follow.
Why follow: Mandrola is a relevant name for readers who want scrutiny alongside enthusiasm for cardiovascular innovation. His commentary offers a route into debates about trial methods, absolute benefit and uncertainty. As with any commentator, the useful approach is to follow the argument back to the study rather than treating an individual interpretation as a substitute for the underlying evidence.
Follow John Mandrola on LinkedIn
Sources: Institutional biography | WebMD/Medscape author biography | Author introduction and podcast context
23. Ritu Thamman
Cardiovascular education, digital ethics and professional communication
Ritu Thamman is a cardiologist and clinical associate professor at the University of Pittsburgh, where she is also affiliated with the Center for Bioethics and Health Law. Her interests bring cardiovascular education into contact with telehealth, AI and health equity. Her university biography describes work in echocardiography, digital ethics and narrative medicine, as well as the creation of the Women in Echo Twitter Journal Club. This combination makes her relevant to how clinicians learn, communicate and consider the wider consequences of technology.
Why follow: Thamman is a useful name for readers who want to connect clinical innovation with professional judgement and education. Her work opens up questions about who is represented in digital discussions, how evidence is explained and what ethical responsibilities accompany new tools. Those questions are especially relevant when a technology changes the relationship between a patient and a clinician.
Follow Ritu Thamman on LinkedIn
Sources: Institutional biography | University of Pittsburgh biography
24. Barbara Casadei
Arrhythmia research and cardiovascular data infrastructure
Barbara Casadei is a cardiologist, British Heart Foundation professor and head of the National Heart and Lung Institute at Imperial College London. She moved to Imperial in 2024 after a long period at Oxford. Her research investigates arrhythmias and their wider cardiovascular consequences, with work involving large datasets and imaging. She is also a founder and co-chair of EuroHeart, an initiative concerned with standardised cardiovascular data and the infrastructure needed for quality improvement and research.
Why follow: Casadei is relevant to readers interested in what makes cardiovascular innovation possible at scale. Her work connects biological questions with the way data is collected and organised. For healthcare leaders, that is a useful perspective on why a promising analytical method still depends on dependable clinical information and research systems around it.
Explore Barbara Casadei’s work at Imperial
Sources: Institutional biography | Imperial research and leadership profile | Imperial appointment announcement, 2024
25. Fausto J. Pinto
Global cardiovascular health and implementation
Fausto J. Pinto is a Lisbon-based cardiologist and a past president of the World Heart Federation, serving in 2021 to 2022. His work brings clinical cardiology into the discussion of cardiovascular health at a population and policy level. The World Heart Federation identifies him as a co-author of its World Heart Report on the global burden of cardiovascular disease. University of Lisbon accounts also document his connection to clinical cardiology and heart failure telemonitoring at Santa Maria Hospital. These are distinct examples of his involvement in global advocacy and care delivery.
Why follow: Pinto is relevant to readers asking how better cardiovascular care reaches different health systems and communities. His work offers a wider frame for innovation, including prevention, service organisation and implementation. That perspective is valuable when a technology discussion needs to account for the settings and resources in which care will actually be delivered.
Follow Fausto J. Pinto on LinkedIn
Sources: Institutional biography | World Heart Federation leadership history | World Heart Report and co-author attribution | University of Lisbon telemonitoring account
Build a feed around the questions that matter
The most useful professional feed is one that helps you ask better questions. For AI and imaging, start with Topol, Khera, or Min. For clinical trials, look at Bhatt, Mehran, Harrington, and Al-Lamee. For prevention and women’s cardiovascular health, explore Blumenthal, Gulati, Michos and Mieres. For remote rhythm care, Mittal and Duncker offer another route in. Use the LinkedIn links and institutional profiles to discover the people, then explore the source material behind their work. A well-designed network can help you follow cardiovascular innovation while keeping its clinical evidence, practical limitations, and human consequences in view. Explore all 25 names in Cardiology: Who to Follow, or browse the wider Who to Follow directory.
